Preoperative Prediction Value of Pelvic Lymph Node Metastasis of Endometrial Cancer: Combining of ADC Value and Radiomics Features of the Primary Lesion and Clinical Parameters
Table 2
Selected clinicopathological data of patients with endometrial cancer.
Characteristics
Training set
Test set
PLNM (+)
PLNM (−)
PLNM (+)
PLNM (−)
Age at onset (years)
55 (51, 63)
53 (49, 61.8)
0.196
54 (49.5, 59)
53 (49, 57.5)
0.227
0.132
CA125 (U/mol)
<0.001
0.007
<0.001
≥35
18 (58.1%)
6 (9.4%)
76.9 (%)
9 (32.1%)
<35
13 (41.9%)
58 (90.6%)
3 (23.1%)
19 (67.9%)
MR-reported Mdot (cm)
5 (3.5, 5.5)
4 (3, 5)
0.034
5 (2.9, 6)
4.3 (2.9, 5.8)
0.555
0.034
MR-reported PLNS
0.009
0.069
<0.001
MR-reported PLNM (+)
20 (64.5%)
8 (12.5%)
6 (46.2%)
4 (14.3%)
MR-reported PLNM (−)
11 (35.5%)
56 (87.5%)
7 (53.8%)
24 (85.7%)
LVSI
<0.001
0.002
<0.001
Present
17 (54.8%)
4 (6.20%)
8 (61.5%)
3 (10.7%)
Absent
14 (45.2%)
60 (93.8%)
5 (38.5%)
25 (89.3%)
Ki-67(%)
60 (50, 70)
50 (30, 70)
0.014
70 (60, 75)
45 (32.5, 67.5)
0.005
<0.001
Adnexal metastasis
<0.001
0.024
<0.001
Present
13 (41.9%)
5 (7.80%)
5 (38.5%)
2 (7.10%)
Absent
18 (58.1%)
59 (92.2%)
8 (61.5%)
26 (92.9%)
Dmi
<0.001
<0.001
<0.001
Present
21 (67.7%)
14 (21.9%)
10 (76.9%)
8 (28.6%)
Absent
10 (32.3%)
50 (78.1%)
3 (23.1%)
20 (71.4%)
Menopause
0.675
0.460
0.912
Present
17 (54.8%)
38 (59.4%)
9 (69.2%)
16 (57.1%)
Absent
14 (45.2%)
26 (40.6%)
4 (30.8%)
12 (42.9%)
FIGO stage
<0.001
<0.001
<0.001
I–II
0
56 (87.5%)
0
25 (89.3%)
IIIA
0
8 (12.5%)
0
3 (10.7%)
IIIC
25 (80.6%)
0
9 (69.2%)
0
IVA
6 (19.4%)
0
2 (15.4%)
0
IVB
0
0
2 (15.4%)
0
Pathological types
0.036
0.443
0.017
Endometrioid
19 (61.3%)
52 (81.2%)
8 (61.5%)
22 (78.6%)
Nonendometrioid
12 (38.7%)
12 (18.8%)
5 (38.5%)
6 (21.4%)
Note. CA125 = carcinoma antigen 125; MR-reported Mdot = MR-reported maximum diameter of tumor; MR-reported; PLNS = MR-reported pelvic lymph node status; LVSI = lymphatic vascular space infiltration; and Dmi = deep myometrial invasion.
